Switching fat from the periphery to bone marrow: why in Type I diabetes?

References

• McCabe LR. Understanding the pathology and mechanisms of Type I diabetic bone loss. J. Cell. Biochem.102(6), 1343–1357 (2007).
   PubMed Web of Science ®Google Scholar
• Hofbauer LC, Brueck CC, Singh SK, Dobnig H. Osteoporosis in patients with diabetes mellitus. J. Bone Miner. Res.22(9), 1317–1328 (2007).
   PubMed Web of Science ®Google Scholar
• Bouillon R, Bex M, Van Herck E et al. Influence of age, sex, and insulin on osteoblast function: osteoblast dysfunction in diabetes mellitus. J. Clin. Endocrinol. Metab.80(4), 1194–1202 (1995).
   PubMed Web of Science ®Google Scholar
• Kemink SA, Hermus AR, Swinkels LM, Lutterman JA, Smals AG. Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. J. Endocrinol. Invest.23(5), 295–303 (2000).
   PubMedGoogle Scholar
• Auwerx J, Dequeker J, Bouillon R, Geusens P, Nijs J. Mineral metabolism and bone mass at peripheral and axial skeleton in diabetes mellitus. Diabetes37(1), 8–12 (1988).
   PubMedGoogle Scholar
• Krakauer JC, McKenna MJ, Buderer NF et al. Bone loss and bone turnover in diabetes. Diabetes44(7), 775–782 (1995).
   PubMed Web of Science ®Google Scholar
• Levin ME, Boisseau VC, Avioli LV. Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes. N. Engl. J. Med.294(5), 241–245 (1976).
   PubMed Web of Science ®Google Scholar
• Tuominen JT, Impivaara O, Puukka P, Ronnemaa T. Bone mineral density in patients with Type 1 and Type 2 diabetes. Diabetes Care22(7), 1196–1200 (1999).
   PubMed Web of Science ®Google Scholar
• Munoz-Torres M, Jodar E, Escobar-Jimenez F, Lopez-Ibarra PJ, Luna JD. Bone mineral density measured by dual x-ray absorptiometry in Spanish patients with insulin-dependent diabetes mellitus. Calcif. Tissue Int.58(5), 316–319 (1996).
   PubMed Web of Science ®Google Scholar
• Buysschaert M, Cauwe F, Jamart J et al. Proximal femur density in Type 1 and 2 diabetic patients. Diabetes Metab.18(1), 32–37 (1992).
   Web of Science ®Google Scholar
• Hadjidakis DJ, Raptis AE, Sfakianakis M, Mylonakis A, Raptis SA. Bone mineral density of both genders in Type 1 diabetes according to bone composition. J. Diabetes Complicat.20(5), 302–307 (2006).
   PubMedGoogle Scholar
• Strotmeyer ES, Cauley JA, Orchard TJ, Steenkiste AR, Dorman JS. Middle-aged premenopausal women with Type 1 diabetes have lower bone mineral density and calcaneal quantitative ultrasound than nondiabetic women. Diabetes Care29(2), 306–311 (2006).
   PubMedGoogle Scholar
• Miao J, Brismar K, Nyren O, Ugarph-Morawski A, Ye W. Elevated hip fracture risk in Type 1 diabetic patients: a population-based cohort study in Sweden. Diabetes Care28(12), 2850–2855 (2005).
   PubMed Web of Science ®Google Scholar
• Botolin S, Faugere MC, Malluche H et al. Increased bone adiposity and peroxisomal proliferator-activated receptor-γ2 expression in Type I diabetic mice. Endocrinology146(8), 3622–3631 (2005).
   PubMed Web of Science ®Google Scholar
• Botolin S, McCabe LR. Bone loss and increased bone adiposity in spontaneous and pharmacologically induced diabetic mice. Endocrinology148(1), 198–205 (2007).
   PubMed Web of Science ®Google Scholar
• Tornvig L, Mosekilde LI, Justesen J, Falk E, Kassem M. Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice. Calcif. Tissue Int.69(1), 46–50 (2001).
   PubMed Web of Science ®Google Scholar
• Lazarenko OP, Rzonca SO, Suva LJ, Lecka-Czernik B. Netoglitazone is a PPAR-γ ligand with selective effects on bone and fat. Bone38(1), 74–84 (2006).
   PubMed Web of Science ®Google Scholar
• Lecka-Czernik B, Moerman EJ, Grant DF et al. Divergent effects of selective peroxisome proliferator-activated receptor-γ 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology143(6), 2376–2384 (2002).
   PubMed Web of Science ®Google Scholar
• Meunier P, Aaron J, Edouard C, Vignon G. Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies. Clin. Orthop.80, 147–154 (1971).
   PubMed Web of Science ®Google Scholar
• Jilka RL, Weinstein RS, Takahashi K, Parfitt AM, Manolagas SC. Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. J. Clin. Invest.97(7), 1732–1740 (1996).
   PubMed Web of Science ®Google Scholar
• Kajkenova O, Lecka-Czernik B, Gubrij I et al. Increased adipogenesis and myelopoiesis in the bone marrow of SAMP6, a murine model of defective osteoblastogenesis and low turnover osteopenia. J. Bone Miner. Res.12(11), 1772–1779 (1997).
   PubMed Web of Science ®Google Scholar
• Verma S, Rajaratnam JH, Denton J, Hoyland JA, Byers RJ. Adipocytic proportion of bone marrow is inversely related to bone formation in osteoporosis. J. Clin. Pathol.55(9), 693–698 (2002).
   PubMed Web of Science ®Google Scholar
• Gimble JM, Zvonic S, Floyd ZE, Kassem M, Nuttall ME. Playing with bone and fat. J. Cell. Biochem.98(2), 251–266 (2006).
   PubMed Web of Science ®Google Scholar
• Di Iorgi N, Rosol M, Mittelman SD, Gilsanz V. Reciprocal relation between marrow adiposity and the amount of bone in the axial and appendicular skeleton of young adults. J. Clin. Endocrinol. Metab.93(6), 2281–2286 (2008).
   PubMedGoogle Scholar
• Akune T, Ohba S, Kamekura S et al. PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J. Clin. Invest.113(6), 846–855 (2004).
   PubMed Web of Science ®Google Scholar
• Cock TA, Back J, Elefteriou F et al. Enhanced bone formation in lipodystrophic PPARγ(hyp/hyp) mice relocates haematopoiesis to the spleen. EMBO Rep.5(10), 1007–1012 (2004).
   PubMed Web of Science ®Google Scholar
• Hwang S, Panicek DM. Magnetic resonance imaging of bone marrow in oncology, part 1. Skeletal Radiol.36(10), 913–920 (2007).
   PubMedGoogle Scholar
• Gimble JM, Nuttall ME. Bone and fat: old questions, new insights. Endocrine23(2–3), 183–188 (2004).
   PubMedGoogle Scholar
• Rosen CJ, Bouxsein ML. Mechanisms of disease: is osteoporosis the obesity of bone? Nat. Clin. Pract. Rheumatol.2(1), 35–43 (2006).
   PubMedGoogle Scholar
• Ahdjoudj S, Lasmoles F, Holy X, Zerath E, Marie PJ. Transforming growth factor β2 inhibits adipocyte differentiation induced by skeletal unloading in rat bone marrow stroma. J. Bone Miner. Res.17(4), 668–677 (2002).
   PubMed Web of Science ®Google Scholar
• Duque G, Rivas D, Li W et al. Age-related bone loss in the LOU/c rat model of healthy ageing. Exp. Gerontol.44(3), 183–189 (2009).
   PubMedGoogle Scholar
• Gealekman O, Burkart A, Chouinard M et al. Enhanced angiogenesis in obesity and in response to PPARγ activators through adipocyte VEGF and ANGPTL4 production. Am. J. Physiol. Endocrinol. Metab.295(5), E1056–E1064 (2008).
   PubMed Web of Science ®Google Scholar
• Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology145(1), 401–406 (2004).
   PubMed Web of Science ®Google Scholar
• Li M, Kim DH, Tsenovoy PL et al. Treatment of obese diabetic mice with a heme oxygenase inducer reduces visceral and subcutaneous adiposity, increases adiponectin levels, and improves insulin sensitivity and glucose tolerance. Diabetes57(6), 1526–1535 (2008).
   PubMed Web of Science ®Google Scholar
• Di Iorgi N, Mittelman SD, Gilsanz V. Differential effect of marrow adiposity and visceral and subcutaneous fat on cardiovascular risk in young, healthy adults. Int. J. Obes. (Lond.)32(12), 1854–1860 (2008).
   PubMed Web of Science ®Google Scholar
• Allison S, Baldock P, Enriquez R et al. Critical interplay between neuropeptide Y and sex steroid pathways in bone and adipose tissue homeostasis. J. Bone Miner. Res. (2008) (Epub ahead of print).
   Google Scholar
• Perrini S, Laviola L, Cignarelli A et al. Fat depot-related differences in gene expression, adiponectin secretion, and insulin action and signalling in human adipocytes differentiated in vitro from precursor stromal cells. Diabetologia51(1), 155–164 (2008).
   PubMed Web of Science ®Google Scholar
• Tran TT, Yamamoto Y, Gesta S, Kahn CR. Beneficial effects of subcutaneous fat transplantation on metabolism. Cell. Metab.7(5), 410–420 (2008).
   PubMed Web of Science ®Google Scholar
• Walker GE, Verti B, Marzullo P et al. Deep subcuta neous adipose tissue: a distinct abdominal adipose depot. Obesity (Silver Spring)15(8), 1933–1943 (2007).
   PubMed Web of Science ®Google Scholar
• Tchkonia T, Lenburg M, Thomou T et al. Identification of depot-specific human fat cell progenitors through distinct expression profiles and developmental gene patterns. Am. J. Physiol. Endocrinol. Metab.292(1), E298–E307 (2007).
   PubMed Web of Science ®Google Scholar
• Macotela Y, Boucher J, Tran TT, Kahn CR. Gender and depot differences in adipocyte insulin sensitivity and glucose metabolism. Diabetes58(4), 803–812 (2009).
   PubMedGoogle Scholar
• Martin LM, McCabe LR. Type I diabetic bone phenotype is location but not gender dependent. Histochem. Cell. Biol.128(2), 125–133 (2007).
   PubMed Web of Science ®Google Scholar
• Hamrick MW, Pennington C, Newton D, Xie D, Isales C. Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone34(3), 376–383 (2004).
   PubMed Web of Science ®Google Scholar
• Motyl KJ, McCabe LR. Leptin treatment prevents Type I diabetic marrow adiposity but not bone loss in mice. J. Cell. Physiol.218(2), 376–384 (2009).
   PubMed Web of Science ®Google Scholar
• Vande Berg BC, Malghem J, Lecouvet FE, Lambert M, Maldague BE. Distribution of serouslike bone marrow changes in the lower limbs of patients with anorexia nervosa: predominant involvement of the distal extremities. AJR Am. J. Roentgenol.166(3), 621–625 (1996).
   PubMed Web of Science ®Google Scholar
• Seaman JP, Kjeldsberg CR, Linker A. Gelatinous transformation of the bone marrow. Hum. Pathol.9(6), 685–692 (1978).
   PubMed Web of Science ®Google Scholar
• Smith RR, Spivak JL. Marrow cell necrosis in anorexia nervosa and involuntary starvation. Br. J. Haematol.60(3), 525–530 (1985).
   PubMedGoogle Scholar
• Mehta K, Gascon P, Robboy S. The gelatinous bone marrow (serous atrophy) in patients with acquired immunodeficiency syndrome. Evidence of excess sulfated glycosaminoglycan. Arch. Pathol. Lab. Med.116(5), 504–508 (1992).
   PubMed Web of Science ®Google Scholar
• Motyl K, McCabe L. Streptozotocin, Type I diabetes severity and bone. Biol. Proced. Online (In press).
   Google Scholar
• Irwin R, Lin HV, Motyl KJ, McCabe LR. Normal bone density obtained in the absence of insulin receptor expression in bone. Endocrinology147(12), 5760–5767 (2006).
   PubMedGoogle Scholar
• Botolin S, McCabe LR. Inhibition of PPARγ prevents Type I diabetic bone marrow adiposity but not bone loss. J. Cell. Physiol.209(3), 967–976 (2006).
   PubMedGoogle Scholar
• Botolin S, McCabe LR. Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. J. Cell. Biochem.99(2), 411–424 (2006).
   PubMed Web of Science ®Google Scholar
• Yoshida O, Inaba M, Terada M et al. Impaired response of human osteosarcoma (MG-63) cells to human parathyroid hormone induced by sustained exposure to high glucose. Miner. Electrolyte Metab.21(1–3), 201–204 (1995).
   PubMedGoogle Scholar
• Terada M, Inaba M, Yano Y et al. Growth-inhibitory effect of a high glucose concentration on osteoblast-like cells. Bone 22(1), 17–23 (1998).
   Google Scholar
• Li YM, Schilling T, Benisch P et al. Effects of high glucose on mesenchymal stem cell proliferation and differentiation. Biochem. Biophys. Res. Commun.363(1), 209–215 (2007).
   PubMedGoogle Scholar
• Balint E, Szabo P, Marshall CF, Sprague SM. Glucose-induced inhibition of in vitro bone mineralization. Bone28(1), 21–28. (2001).
   PubMed Web of Science ®Google Scholar
• Motyl KJ, Botolin S, Irwin R et al. Bone inflammation and altered gene expression with Type I diabetes early onset. J. Cell. Physiol.218(3), 575–583 (2009).
   PubMed Web of Science ®Google Scholar
• Gilbert L, He X, Farmer P et al. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2α A) is inhibited by tumor necrosis factor-α. J. Biol. Chem.277(4), 2695–2701 (2002).
   PubMed Web of Science ®Google Scholar
• Nanes MS. Tumor necrosis factor-α: molecular and cellular mechanisms in skeletal pathology. Gene321, 1–15 (2003).
   PubMed Web of Science ®Google Scholar
• Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NFκB ligand and tumor necrosis factor-α in bone destruction in rheumatoid arthritis. Bone30(2), 340–346 (2002).
   PubMed Web of Science ®Google Scholar
• Zhou FH, Foster BK, Zhou XF, Cowin AJ, Xian CJ. TNF-α mediates p38 MAP kinase activation and negatively regulates bone formation at the injured growth plate in rats. J. Bone Miner. Res.21(7), 1075–1088 (2006).
   PubMed Web of Science ®Google Scholar
• Christopher MJ, Link DC. Granulocyte colony-stimulating factor induces osteoblast apoptosis and inhibits osteoblast differentiation. J. Bone Miner. Res.23(11), 1765–1774 (2008).
   PubMed Web of Science ®Google Scholar